News

Pathway in Brain Contributes to Alzheimer’s Disease

A new study entitled “Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer’s Disease,” published in the online issue of Neuron, reports the discovery of a key pathway to the progression of Alzheimer’s Disease. Alzheimer’s disease is characterized by synaptic…

UN Expert Highlights Need to Protect Dementia Patients’ Human Rights

An independent expert from the United Nations recently alerted the organization’s member states on the need to protect dementia patients, especially older ones, from stigmatization, discrimination, victimization, and neglect, as he spoke to celebrate the World Alzheimer’s Day, which is marked annually on September 21th. The UN believes that concerted actions are needed in…

Alzheimer’s Research UK Funds Manchester University Project on Alzheimer’s Brain’s Molecular Map

A research project designed to create a molecular map with thousands of proteins in the brain with Alzheimer’s disease, conducted by Dr. Richard Unwin, from The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust has been granted a £30,000 ($48,600 dollars) award by Alzheimer’s Research UK. The…

Big Data: the Newest Tool in Fighting Alzheimer’s, Dementia

Experts from around the globe gathered in Toronto last week to discuss new approaches to the challenge increasing rates dementia present at an Organization for Economic Co-operation and Development (OECD) workshop organized in partnership with the Ontario Brain Institute (OBI) and the Institute of Health Policy, Management…

Congressman Fattah Plans International Agenda for Dementia

Pennsylvania-based Representative Chaka Fattah — a U.S. Congressman behind the Fattah Neuroscience Initiative, which aims to drive collaborative Federal research on brain cognition, development, disease and injury — recently had a meeting with World Dementia Envoy and head of the World Dementia Council, Dr. Dennis Gillings, to…

New Experimental Therapy For Alzheimer’s Agitation Shows Promise

Avanir Pharmaceuticals Inc. reported today new, positive results for their leading drug, AVP-923, designed to treat agitation in Alzheimer’s disease patients. The results will be presented at the American Neurological Association’s (ANA) 2014 Annual Meeting in Baltimore, MD, October 12-14, 2014. Joao Siffert, MD, chief medical officer at Avanir,…